The Wistar Institute Cancer Center
The first National Cancer Institute-designated Cancer Center in the nation for basic research since 1972.
The mission of The Wistar Institute Cancer Center is to merge basic, translational and disease-relevant cancer research in a single scientific continuum with focus on cancer prevention, diagnosis and therapy. The Cancer Center has a history of significant advances in cancer genetics, cancer biology, tumor immunology, and virology, including the identification of genes associated with different tumor types, the development of monoclonal antibodies used to study pathways and proteins involved in tumor development, and contributions to improved cancer treatments and diagnostic tests.
The Wistar Institute Cancer Center is structured into three research programs. Taking an interdisciplinary approach to cancer research, our scientists are working to advance knowledge in the following areas:
- The molecular pathways underlying some of the most prevalent and deadly types of cancer, to develop new targeted therapies and move forward in the direction of personalized cancer treatment
- The crosstalk between tumor cells and the tumor microenvironment and how it orchestrates tumor progression and response to therapy
- Cancer genomics and epigenetics
- The mechanisms of therapy resistance and how they can be overcome
- Tumor immunology and immunotherapy
- Tumor cell metabolism and how it affects metastatic competence
The leadership of the Cancer Center, supported by internal advisory committees and the Cancer Center External Advisory Board, develops the Center’s goals and leads in the implementation of strategic directives. In addition, the Institute's External Advisory Board meets yearly to review the Center’s programs and plans for recruitment and research.
Dario C. Altieri, M.D., Director
Rugang Zhang, Ph.D., Deputy Director
Research Program Leaders
Gene Expression and Regulation Program
Program Leader: Paul Lieberman, Ph.D.
Program Co-Leader: Bin Tian, Ph.D.
Immunology, Microenvironment & Metastasis Program
Program Leader: Rugang Zhang, Ph.D.
Molecular and Cellular Oncogenesis Program
Program Leader: Maureen Murphy, Ph.D.
Program Co-Leader: David W. Speicher, Ph.D.
Michele Conlin, Associate Director for Finance
Mark Drinker, Associate Director for Administration
Luis J. Montaner, D.V.M., D.Phil., Associate Director for Shared Resources
Nicholas J. Petrelli, M.D., Associate Director for Translational Research
Italo Tempera, Ph.D., Associate Director for Education
For more information on The Wistar Institute Cancer Center, please contact:
Wistar Celebrates 10 Years as a CEO Cancer Gold Standard Employer
Wistar is committed to spreading awareness about cancer prevention among its employees. The accreditation recognizes employers who prioritize workplace wellness initiatives and a commitment to a tobacco-free work environment.